Antiretrovirals that achieve adequate concentrations in anatomical sites of transmission are of interest for HIV prevention. A Phase I open-label pharmacokinetic (PK) study was performed to describe first dose (PK1) and steady-state (PK2) PKs of the integrase inhibitor dolutegravir (DTG) in blood plasma (BP), cervicovaginal fluid (CVF), cervical tissue (CT) and vaginal tissue (VT) in HIV type-1-negative women.
Methods
A total of 8 healthy females given DTG 50 mg daily for 5–7 days had 11 paired BP and CVF samples collected over 24 h following the first dose (PK1) and multiple dosing (PK2). Each woman underwent CT and VT biopsies at 1/4 time points at PK1 and PK2 to generate composite PK profiles. DTG concentrations were analysed by validated liquid chromatography-tandem mass spectrometry methods. Non-compartmental PK analysis was performed and Spearman rank correlations determined between matrices.
Results
BP areas under the concentration–time curve (AUCs) were similar to previous reports and concentrations remained greater than the protein-adjusted (PA) 90% inhibitory concentration (IC90) for wild-type HIV (64 ng/ml). CVF exposures were approximately 6% of BP with low inter-individual variability. CT and VT exposures were 7% of BP at PK1, and 9–10% of BP at PK2 with 94% of samples >PA-IC90. CT and VT concentrations were correlated to each other (ρ=0.70, P=0.003), and to CVF at steady state (ρ=0.52, P=0.04). Accumulation of DTG from PK1 to PK2 occurred in BP, CT and VT, but only marginally in CVF.
Conclusions
DTG BP PK were consistent with previously published values. CVF, CT and VT exposures were highly correlated. At PK2, DTG accumulated to a greater extent in tissue than in BP or CVF, suggesting increased tissue affinity.
References
1.
van LunzenJ., MaggioloF., ArribasJ.R.Once-daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis2012; 12: 111–118.
2.
RaffF., RachlisA., StellbrinkH.J.Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet2013; 381: 735–743.
3.
WalmsleyS., AntelaA., ClumeckN.Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results –SINGLE (ING114467).52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 9–12 September 2012, San Francisco, CA, USA. Abstract H-556b.
4.
EronJ.J., ClotetB., DurantJ.Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis2013; 207: 740–748.
5.
DonnellD., BaetenJ.M., KiarieJ.Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet2010; 375: 2092–2098.
6.
GrahamS.M., HolteM., SarahE.Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS2007; 21: 501–507.
7.
CohenM.S., MuessigK.E., SmithM.K., PowersK.A., KashubaA.D.Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS2012; 26: 1585–1598.
8.
CohenM.S., ChenY.Q., McCauleyM.Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med2011; 365: 493–505.
9.
Van DammeL., CorneliA., AhmedK.Preexposure prophylaxis for HIV infection among African women. N Engl J Med2012; 367: 411–422.
10.
BaetenJ.M., DonnellD., NdaseP.Antiretriviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med2012; 367: 399–410.
11.
ThigpenM.C., KebaabetsweP.M., PaxtonL.A.Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med2012; 367: 423–434.
12.
DumondJ.B., YehR.F., PattersonK.B.Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS2007; 21: 1899–1907.
13.
MinS., SloanL., DeJesusE.Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS2011; 25: 1737–1745.
14.
MinS., SongI., BorlandJ.Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother2010; 54: 254–258.
15.
MinS.S., CorbettA.H., RezkN.Protease inhibitor and non-nucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr2004; 37: 1577–1580.
PattersonK.B., PrinceH.A., WhiteN.Pharmacokinetics (PK) of raltegravir (RAL) in the blood plasma (BP) and genital tract (GT) in HIV+ and HIV- women.XVIII International AIDS Conference. 18–23 July 2010, Vienna, Austria. Poster LBPE18.
18.
JonesA.E., TalamehJ., PattersonK.First-dose and steady-state pharmacokinetics of raltegravir in the genital tract of HIV-negative women.10th International Workshop on Clinical Pharmacology of HIV Therapy. 15–17 April 2009, Amsterdam, the Netherlands. Abstract 0-06.
19.
ClavelC., PeytavinG., TubianaR.Raltegravir concentrations in the genital tract of HIV-infected women treated with a raltegravir-containing regimen (DIVA 01 Study). Antimicrob Agents Chemother2011; 55: 3018–3021.
20.
RamanathanS., MathiaA., GermanP., KearneyB.P.Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet2011; 50: 229–244.
21.
Salas HerreraI.G., PearsonR.M., TurnerP.Quantitation of albumin and alpha-1-acid glycoprotein in human cervical mucus. Hum Exp Toxicol1991; 10: 137–139.
22.
DumondJ.B., PattersonK.B., PechaA.L.Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr2009; 51: 546–553.
